 For its part, Eli Lilly, which makes trulicity in Manjaro, has made public statements against using GLP-1 drugs for, quote, cosmetic weight loss. And Novo Nordisk says its direct-to-consumer advertising is meant to educate patients, not promote off-label use. Still, it turns out that conserving these medications for the people they were approved to treat is challenging. CVS Caremark's solution involves looking at a patient's history to see whether there's any prior evidence of them having diabetes.